Fetal exposure to oncoantigen elicited antigen-specific adaptive immunity against tumorigenesis.
adaptive immunity
immunologic surveillance
macrophages
oncology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
12
05
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
17
3
2021
Statut:
ppublish
Résumé
Envisioned as a similar process to tumorigenesis in terms of biological behaviors and molecular basis, embryogenesis necessitates an immune surveillance system to eliminate erratically transformed cells. Our previous study demonstrated that fetal macrophage-like phagocytes triggered Th2-skewed immunity following endocytosing prenatally administered ovalbumin to facilitate postnatal allergic airway responses, highlighting the critical role fetal phagocytes played in dealing with antigens present in developing fetuses and shaping subsequent immune responses. It prompted us to examine whether fetuses could mount Th1 tumoricidal immunity against tumorigenesis following in utero exposure to tumor antigens. Gestational day 14 murine fetuses underwent in utero injection of Th1-promoting human papilloma virus (HPV) E7 peptides. Postnatally, recipients were examined for immunological consequences and the resistance to TC-1 tumorigenesis. Fetal exposure to HPV E7 did not cause tolerance but rather immunization in the recipients, characterized by proinflammatory Th1 polarization of their lymphocytes. Fetal macrophage-like phagocytes were responsible for taking up HPV E7 and triggering HPV E7-specific T-cell cytotoxicity and humoral immunity that rendered recipients resistant to TC-1 tumorigenesis in postnatal life. Adoptive transfer of HPV E7-loaded fetal phagocytes also elicited Th1 immunity with rapid expansion of HPV E7-specific cytotoxic CD8 Our study revealed that Th2-biasing fetus was not immune-privileged to foreign peptides, but competent to mount Th1 cytotoxic immunity and generate immunoglobulins against tumorigenesis following in utero exposure to Th1-promoting oncoantigen. It shed light on the role of fetal macrophage-like phagocytes in bridging toward tumor antigen-specific cellular and humoral immunity potentially as an immune surveillance system to eliminate transformed cells that might be egressing during embryogenesis and leftover until postnatal life.
Sections du résumé
BACKGROUND
Envisioned as a similar process to tumorigenesis in terms of biological behaviors and molecular basis, embryogenesis necessitates an immune surveillance system to eliminate erratically transformed cells. Our previous study demonstrated that fetal macrophage-like phagocytes triggered Th2-skewed immunity following endocytosing prenatally administered ovalbumin to facilitate postnatal allergic airway responses, highlighting the critical role fetal phagocytes played in dealing with antigens present in developing fetuses and shaping subsequent immune responses. It prompted us to examine whether fetuses could mount Th1 tumoricidal immunity against tumorigenesis following in utero exposure to tumor antigens.
METHODS
Gestational day 14 murine fetuses underwent in utero injection of Th1-promoting human papilloma virus (HPV) E7 peptides. Postnatally, recipients were examined for immunological consequences and the resistance to TC-1 tumorigenesis.
RESULTS
Fetal exposure to HPV E7 did not cause tolerance but rather immunization in the recipients, characterized by proinflammatory Th1 polarization of their lymphocytes. Fetal macrophage-like phagocytes were responsible for taking up HPV E7 and triggering HPV E7-specific T-cell cytotoxicity and humoral immunity that rendered recipients resistant to TC-1 tumorigenesis in postnatal life. Adoptive transfer of HPV E7-loaded fetal phagocytes also elicited Th1 immunity with rapid expansion of HPV E7-specific cytotoxic CD8
CONCLUSIONS
Our study revealed that Th2-biasing fetus was not immune-privileged to foreign peptides, but competent to mount Th1 cytotoxic immunity and generate immunoglobulins against tumorigenesis following in utero exposure to Th1-promoting oncoantigen. It shed light on the role of fetal macrophage-like phagocytes in bridging toward tumor antigen-specific cellular and humoral immunity potentially as an immune surveillance system to eliminate transformed cells that might be egressing during embryogenesis and leftover until postnatal life.
Identifiants
pubmed: 32561637
pii: jitc-2019-000137
doi: 10.1136/jitc-2019-000137
pmc: PMC7304846
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Papillomavirus E7 Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Sci Rep. 2019 May 22;9(1):7677
pubmed: 31118442
Trends Immunol. 2010 Jun;31(6):212-9
pubmed: 20452821
Eur J Immunol. 2011 Sep;41(9):2472-6
pubmed: 21952799
Nat Immunol. 2008 May;9(5):477-80
pubmed: 18425103
Front Immunol. 2017 Jul 14;8:828
pubmed: 28769933
Cell Transplant. 2010;19(12):1609-22
pubmed: 20719075
Diabetes. 2008 Dec;57(12):3239-46
pubmed: 18829989
Cancer Res. 2015 Dec 1;75(23):5008-13
pubmed: 26573795
Int J Dev Biol. 1993 Mar;37(1):33-7
pubmed: 8507567
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Vaccine. 2000 Jul 15;18(27):3174-84
pubmed: 10856797
Science. 1996 Jun 7;272(5267):1405-8
pubmed: 8633222
Nat Immunol. 2016 Jan;17(1):2-8
pubmed: 26681456
Sci Transl Med. 2012 Oct 10;4(155):155ra138
pubmed: 23052295
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2049-54
pubmed: 16609014
Science. 1996 Mar 22;271(5256):1665-7
pubmed: 8596923
J Leukoc Biol. 2009 Nov;86(5):1105-9
pubmed: 19605698
Immunol Rev. 2006 Dec;214:56-72
pubmed: 17100876
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16232-6
pubmed: 12446839
J Immunol. 2017 Oct 1;199(7):2191-2193
pubmed: 28923980
Trends Cancer. 2016 Oct 1;2(1):20-34
pubmed: 26949745
Science. 2016 Sep 9;353(6304):
pubmed: 27492475
Crit Rev Oncol Hematol. 2002 Nov;44(2):143-61
pubmed: 12413632
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
Am J Respir Crit Care Med. 2016 Oct 15;194(8):934-947
pubmed: 27064309
Nature. 1953 Oct 3;172(4379):603-6
pubmed: 13099277
Cell Tissue Res. 2018 May;372(2):277-286
pubmed: 29305654
Nat Commun. 2017 Jul 24;8:16041
pubmed: 28737175
Cancer Res. 1996 Jan 15;56(2):362-9
pubmed: 8542593
Mol Cell Biol. 2002 Nov;22(22):8035-43
pubmed: 12391169
Exp Hematol. 2000 Jun;28(6):601-11
pubmed: 10880746
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Blood. 1995 Dec 15;86(12):4681-90
pubmed: 8541562
Clin Chem. 2013 Jan;59(1):85-93
pubmed: 23193058
J Immunother. 2017 Feb/Mar;40(2):62-70
pubmed: 28166181
Front Immunol. 2018 Mar 02;9:418
pubmed: 29552016
J Immunol. 2004 May 15;172(10):6136-43
pubmed: 15128800
Science. 1996 Mar 22;271(5256):1728-30
pubmed: 8596934
J Cell Mol Med. 2010 Dec;14(12):2697-701
pubmed: 21029369
Nat Immunol. 2007 Feb;8(2):111-3
pubmed: 17242678
Nature. 2015 Feb 26;518(7540):547-51
pubmed: 25470051
Traffic. 2018 Apr;19(4):273-284
pubmed: 29437282
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9358-65
pubmed: 8790334
Clin Cancer Res. 2008 Jan 1;14(1):169-77
pubmed: 18172268
PLoS One. 2014 Sep 29;9(9):e108892
pubmed: 25265018
BMC Immunol. 2018 Jan 24;19(1):3
pubmed: 29361917
Nature. 1997 Aug 21;388(6644):787-92
pubmed: 9285592
Immunol Today. 1993 Jul;14(7):353-6
pubmed: 8363725
J Cell Mol Med. 2016 Jun;20(6):1024-35
pubmed: 26843477
Immunology. 1997 Aug;91(4):635-42
pubmed: 9378506